All data are based on the daily closing price as of January 23, 2025
s

SCI Pharmtech

4119.TW
2.62 USD
0.03
+1.16%

Overview

Last close
2.62 usd
Market cap
312.98M usd
52 week high
3.23 usd
52 week low
2.53 usd
Target price
2.33 usd

Valuation

P/E
21.4787
Forward P/E
N/A
Price/Sales
8.1814
Price/Book Value
1.8893
Enterprise Value
329.43M usd
EV/Revenue
7.6431
EV/EBITDA
13.3826

Key financials

Revenue TTM
38.18M usd
Gross Profit TTM
10.59M usd
EBITDA TTM
10.22M usd
Earnings per Share
0.12 usd
Dividend
N/A usd
Total assets
227.59M usd
Net debt
18.56M usd

About

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, the Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.
  • Symbol
    4119.TW
  • Exchange
    TW
  • Isin
    TW0004119003
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
  • Headquarter
    Taoyuan City
  • Web site
    https://www.sci-pharmtech.com.tw
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top